Advances in high‐throughput mass spectrometry in drug discovery
Abstract High‐throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines. Recent technological developments in mass spectrometry (MS) and automation have...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2023-01-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202114850 |
| _version_ | 1797285784763498496 |
|---|---|
| author | Maria Emilia Dueñas Rachel E Peltier‐Heap Melanie Leveridge Roland S Annan Frank H Büttner Matthias Trost |
| author_facet | Maria Emilia Dueñas Rachel E Peltier‐Heap Melanie Leveridge Roland S Annan Frank H Büttner Matthias Trost |
| author_sort | Maria Emilia Dueñas |
| collection | DOAJ |
| description | Abstract High‐throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines. Recent technological developments in mass spectrometry (MS) and automation have revolutionized the application of MS for use in HT screens. These methods allow the targeting of unlabelled biomolecules in HT assays, thereby expanding the breadth of targets for which HT assays can be developed compared to traditional approaches. Moreover, these label‐free MS assays are often cheaper, faster, and more physiologically relevant than competing assay technologies. In this review, we will describe current MS techniques used in drug discovery and explain their advantages and disadvantages. We will highlight the power of mass spectrometry in label‐free in vitro assays, and its application for setting up multiplexed cellular phenotypic assays, providing an exciting new tool for screening compounds in cell lines, and even primary cells. Finally, we will give an outlook on how technological advances will increase the future use and the capabilities of mass spectrometry in drug discovery. |
| first_indexed | 2024-03-07T18:07:18Z |
| format | Article |
| id | doaj.art-2cf14ad9b34d44d7be9f8dc1ffb61354 |
| institution | Directory Open Access Journal |
| issn | 1757-4676 1757-4684 |
| language | English |
| last_indexed | 2024-03-07T18:07:18Z |
| publishDate | 2023-01-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj.art-2cf14ad9b34d44d7be9f8dc1ffb613542024-03-02T08:17:10ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842023-01-01151n/an/a10.15252/emmm.202114850Advances in high‐throughput mass spectrometry in drug discoveryMaria Emilia Dueñas0Rachel E Peltier‐Heap1Melanie Leveridge2Roland S Annan3Frank H Büttner4Matthias Trost5Laboratory for Biomedical Mass Spectrometry, Biosciences Institute Newcastle University Newcastle‐upon‐Tyne UKDiscovery Analytical, Screening Profiling and Mechanistic Biology, GSK R&D Stevenage UKDiscovery Analytical, Screening Profiling and Mechanistic Biology, GSK R&D Stevenage UKDiscovery Analytical, Screening Profiling and Mechanistic Biology, GSK R&D Stevenage UKDrug Discovery Sciences, High Throughput Biology Boehringer Ingelheim Pharma GmbH&CoKG Biberach GermanyLaboratory for Biomedical Mass Spectrometry, Biosciences Institute Newcastle University Newcastle‐upon‐Tyne UKAbstract High‐throughput (HT) screening drug discovery, during which thousands or millions of compounds are screened, remains the key methodology for identifying active chemical matter in early drug discovery pipelines. Recent technological developments in mass spectrometry (MS) and automation have revolutionized the application of MS for use in HT screens. These methods allow the targeting of unlabelled biomolecules in HT assays, thereby expanding the breadth of targets for which HT assays can be developed compared to traditional approaches. Moreover, these label‐free MS assays are often cheaper, faster, and more physiologically relevant than competing assay technologies. In this review, we will describe current MS techniques used in drug discovery and explain their advantages and disadvantages. We will highlight the power of mass spectrometry in label‐free in vitro assays, and its application for setting up multiplexed cellular phenotypic assays, providing an exciting new tool for screening compounds in cell lines, and even primary cells. Finally, we will give an outlook on how technological advances will increase the future use and the capabilities of mass spectrometry in drug discovery.https://doi.org/10.15252/emmm.202114850affinity selectiondrug discoveryhigh‐throughput screeningMALDI‐TOFmass spectrometry |
| spellingShingle | Maria Emilia Dueñas Rachel E Peltier‐Heap Melanie Leveridge Roland S Annan Frank H Büttner Matthias Trost Advances in high‐throughput mass spectrometry in drug discovery EMBO Molecular Medicine affinity selection drug discovery high‐throughput screening MALDI‐TOF mass spectrometry |
| title | Advances in high‐throughput mass spectrometry in drug discovery |
| title_full | Advances in high‐throughput mass spectrometry in drug discovery |
| title_fullStr | Advances in high‐throughput mass spectrometry in drug discovery |
| title_full_unstemmed | Advances in high‐throughput mass spectrometry in drug discovery |
| title_short | Advances in high‐throughput mass spectrometry in drug discovery |
| title_sort | advances in high throughput mass spectrometry in drug discovery |
| topic | affinity selection drug discovery high‐throughput screening MALDI‐TOF mass spectrometry |
| url | https://doi.org/10.15252/emmm.202114850 |
| work_keys_str_mv | AT mariaemiliaduenas advancesinhighthroughputmassspectrometryindrugdiscovery AT rachelepeltierheap advancesinhighthroughputmassspectrometryindrugdiscovery AT melanieleveridge advancesinhighthroughputmassspectrometryindrugdiscovery AT rolandsannan advancesinhighthroughputmassspectrometryindrugdiscovery AT frankhbuttner advancesinhighthroughputmassspectrometryindrugdiscovery AT matthiastrost advancesinhighthroughputmassspectrometryindrugdiscovery |